ORIC Pharmaceuticals, Inc. Stock Analysis & AI Score
ORIC Pharmaceuticals, Inc. (ORIC) has an ST Score of 59.7 (B-), driven by its Financial Strength (A) and held back by its Growth (D+). Analysts rate it Buy with a $22.67 price target (+72.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
ORIC Pharmaceuticals, Inc. (ORIC) has an ST Score of 59.7 (B-), driven by its Financial Strength (A) and held back by its Growth (D+). Analysts rate it Buy with a $22.67 price target (+72.0% upside).
- Strongest
- Financial StrengthA
- Weakest
- GrowthD+
All factor grades
- Financial StrengthA
- ValuationA-
- MomentumA-
- ForecastB+
- ProfitabilityB-
- GrowthD+
- Piotroski1/9
Contact
ORIC stock: frequently asked questions
What is ORIC's ST Score?
ORIC Pharmaceuticals, Inc. (ORIC) has an ST Score of 59.7 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ORIC a buy, hold, or sell?
Analysts rate ORIC a Buy, with a price target of $22.67 (+72.0% vs the current price). Our ST Score grades it B- (59.7/100). The ST Score is a data-driven signal, not a recommendation.
What are ORIC's factor grades?
Valuation A-, Profitability B-, Financial Strength A, Momentum A-, Growth D+, Forecast B+.
What is ORIC's valuation grade?
ORIC Pharmaceuticals, Inc. (ORIC) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ORIC's growth grade?
ORIC Pharmaceuticals, Inc. (ORIC) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ORIC's profitability grade?
ORIC Pharmaceuticals, Inc. (ORIC) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ORIC's financial strength grade?
ORIC Pharmaceuticals, Inc. (ORIC) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ORIC?
The average analyst price target for ORIC Pharmaceuticals, Inc. (ORIC) is $22.67 from 10 analysts, which is +72.0% versus the recent price of $13.18.
What is ORIC's Piotroski score?
ORIC Pharmaceuticals, Inc. (ORIC) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.